Asset Details
Do you wish to reserve the book?
EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer
Do you wish to request the book?
EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer
2019
Overview
Introduction/BackgroundThe aim of the study was to evaluate site of splenic metastases and ıts affect on survival in advanced stage epithelial ovarian cancer.MethodologyThis retrospective study was done in Baskent University School of Medicine, Ankara, Turkey. We evaluated 182 patients who underwent splenectomy as a part of primary cytoreductive surgery between 2008–2018 Besides we invastegated 2,3 and 5 year overall survival rates.ResultsMedian age was 61 years (27–81),Median lenght of stay was 13 days (4–87 days). 40 (21,7%) patients had paranchimal and 144 (78,3%) had non paranchimal (Hilar or capsular) metastases,Median overal survival was 27 months and 31 months respectively(p=0,6).ConclusionSplenectomy in primary cytoreductive surgery is an effective intervention to achive R0 resection in advanced stage EOC However site of splenic metastases has no impact on short term and long term overall survival.DisclosureNothing to disclose.Abstract EP773 Table 1Median Overall Survival rates According to site of Splenic Metastases Site of Metastases Number Median Overall Survival (Months) 2 year OS 3 Year OS 5 year OS p value Paranhimal 40 27 62% 41% 23,5% 0,6 Non-Paranchimal 142 31 60% 44% 26%
Publisher
Elsevier Inc,Elsevier Limited
Subject
